Navigation Links
Video: FDA States Consumers Should Continue to Use alli
Date:9/2/2009

PARSIPPANY, N.J., Sept. 2 /PRNewswire/ -- The following is an updated GlaxoSmithKline Consumer Healthcare statement in response to the FDA's Early Communication about the safety review of orlistat:

On August 24th the FDA reported that it is continuing its safety review of orlistat and liver-related serious adverse events.

To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/alli/39949/

It's important consumers know that alli is safe and effective and there's no evidence to suggest alli causes liver injury. In fact, the FDA has said that consumers should continue to use alli as directed.

Because orlistat is minimally absorbed in the blood and works locally in the gastro-intestinal tract, there is no obvious biological mechanism to suggest liver injury can occur with alli.

To put FDA's communication into perspective, there is a high prevalence of liver disease in people who are overweight. It is estimated that about 15-20% of obese people have liver injury due to excessive fat in the liver.[1] Additionally, in obese individuals, gradual weight loss can prevent injury or improve liver function.

The August 24th communication is part of FDA's current process of sharing information directly with consumers and healthcare professional related to the safety monitoring of marketed drug products. This does not mean that FDA has concluded that there is a risk.

Since orlistat first became available as a prescription medicine in 1998, more than 40 million people have used the drug. Of these, more than 6 million have used alli, the only FDA-approved over-the-counter weight loss product. The FDA identified two reports of liver injury out of the six million consumers who have used alli since its approval in 2007.

Orlistat, the active ingredient in alli, is the most-studied weight loss medicine. Its safety has been established through 100 clinical studies involving more than 30,000 patients.

GSK continues to proactively monitor the safety of orlistat and share all relevant information with regulatory agencies. Based on our comprehensive review of the safety data from preclinical and clinical, post-marketing safety surveillance, published literature as well as epidemiology data, we conclude that the data do not suggest that orlistat is causally related to liver injury.

We are actively working with the FDA to better understand the reports it has received. If you have concerns, you should talk to your doctor or pharmacist. For more information on the safety and efficacy of alli, please visit www.myalli.com and/or call 1-800-671-2554.

[1] Preiss, D., Sattar, N. Non-alcoholic fatty liver disease: An overview of prevalence, diagnosis, pathogenesis and treatment considerations. (2008) Clinical Science, 115 (5-6), pp. 141-150.

    FOR ACCESS TO EXPERT COMMENT:
    Malesia Dunn
    malesia.a.dunn@gsk.com
    412-200-3544

    Mechal Weiss
    mechal.weiss@edelman.com
    212-642-7731
    917-952-4807


'/>"/>
SOURCE GlaxoSmithKline
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Video: Renowned Health Expert Dra. Aliza Teams Up With Baby Looney Tunes To Promote Healthy, Happy Babies
2. Video: Life Insurance Awareness Month is the Ideal Time for an Insurance Review
3. Video: Physical and Mental Health of U.S. Warfighter Is Focus of Military Health Research Forum
4. Video: Project Runway Designer Launches New Online Video Series to Educate About Living with HIV and AIDS and Help Combat HIV Stigma
5. Video: New Insights Link Low HDL-Cholesterol and Elevated Triglycerides with Coronary Heart Disease and Microvascular Complications in Patients at Goal for LDL-Cholesterol
6. Video: HHS Launches Best Bones Forever!
7. Video: CVS/pharmacy and MinuteClinic Encourage Americans to Protect Themselves Early With a Seasonal Flu Shot
8. Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients
9. Video: Phase III Head to Head Trial Showed Ticagrelor Reduced Cardiovascular Death and Heart Attacks Over Clopidogrel in Acute Coronary Syndromes Patients
10. Video: AstraZeneca Traveling Exhibit Helps Americans Understand and Manage Bipolar Depression
11. Video: School Nurses Tackle Low Parental Awareness of Meningitis Via Comprehensive National Public Education Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... ... the launch of a Kickstarter crowd funding campaign ( http://kck.st/2g3a1so ) for the ... active alerts and even taking an EKG from the watch while sharing these ...
(Date:12/6/2016)... CA (PRWEB) , ... December 06, 2016 , ... 'Tis ... can disrupt daily routines. That means it's also the season when eating healthy, staying ... living with diabetes) on schedule is harder to do. , "Shopping trips, parties ...
(Date:12/6/2016)... ... December 06, 2016 , ... “Tatiana Sibirskaya: A Life ... story of sacrifice and enlightenment. , “Tatiana Sibirskaya: A Life Devoted ... looking for creative outlets, Carolyn gravitated toward writing through the inspiration of her ...
(Date:12/6/2016)... ... 06, 2016 , ... TopConsumerReviews.com recently gave a best-in-class 5 star rating to ... give freedom to people who need help getting around. For some, advancing age has ... period of rehabilitation after an illness or accident. There is a wide variety of ...
(Date:12/6/2016)... ... December 06, 2016 , ... "Add realistic flares and light leaks to ... from clip to clip with high quality 4K lens flare footage," said Christina Austin ... lens flares filmed on the RED Dragon. Utilizing the Dragon Sensor, TransFlare 4K Jewel ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... , Dec. 6, 2016  Viking Therapeutics, ... clinical-stage biopharmaceutical company focused on the development of ... announced that the U.S. Food and Drug Administration ... for the treatment of X-linked adrenoleukodystrophy (X-ALD).  VK0214 ... (TRß) agonist that selectively regulates the expression of ...
(Date:12/6/2016)... , Dec. 6, 2016 A new study ... of 340B (AIR 340B) projects the 340B Drug Pricing Program ... by which time it is expected to exceed $23 billion ... would see 340B purchases surpass current Medicare Part B drug ... The new study – based on analysis of data on ...
(Date:12/6/2016)... , Dec. 6, 2016  BioAtla, LLC, ... development of Conditionally Active Biologic (CAB) antibody ... Sinobioway Group Company, Limited (Sinobioway) selected their ... The specific program candidates and the targeted ... BioAtla and Sinobioway entered into a strategic ...
Breaking Medicine Technology: